Resistance to inhibitors of the human immunodeficiency virus type 1 integration

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 5, 2010, Pages 513-518

  Hazuda, Daria J ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antiretrovirals; Integrase inhibitors; Raltegravir

Indexed keywords

ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE; INTEGRASE INHIBITOR; MK 0581; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; DRUG BINDING; DRUG MECHANISM; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VIRUS DNA CELL DNA INTERACTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 78951476418     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702010000500016     Document Type: Review

References (46)

1. Cahn P, Sued O. Raltegravir: a new antiretroviral class for salvage therapy. Lancet 2007; 369:1235-1236.
2. Brown PO. Retroviruses. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York, 1998.
3. Chiu TK, Davies DR. Structure and function of HIV-1 integrase. Curr Top Med Chem 2004; 4(9):965-77.
4. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001; 276(26):23213-6.
5. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 1991; 67(6):1211-1221.
6. Young SD. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr Opin Drug Discov Devel 2001; 4(4):402-10.
7. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004; 4(10):1059-77.
8. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov 2005; 4(3):236-248.
9. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. Embo J 1990; 9(5):1551-60.
10. Wiskerchen M, Muesing MA. Human immunodefi ciency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells. J Virol 1995; 69(1):376-86.
11. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287(5453):646-50.
12. Buzón M, Massanella M, Llibre JM et al. HIV-1 replication and immune dynamics are affected by raltegravir intensifi cation of HAART-suppressed subjects. Nature Medicine 2010; 16:460-465.
13. Espeseth AS, Felock, P, Wolfe A et al. HIV-1 integrase inhibitors that compete with the target DNA substrate defi ne a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000; 97(21):11244-9.
14. Grobler JA, Stillmock K, Hu B et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002; 99(10):6661-6.
15. Hare S, Gupta SS, Volkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010; 464(7286):232-236.
16. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 1998; 282(2):359-68.
17. Damond F, Lariven S, Roquebert B et al. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22(5):665-6.
18. Danovich R, Ke Y, Wan H et al. Raltegravir has similar in vitro antiviral potency, clinical effi cacy, and resistance patterns in B subtype and non-B subtype HIV-1. In: Abstracts of the Seventeenth International AIDS Conference, Mexico City, 2008. Abstract TUAA0302.
19. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22(9):1091-112.
20. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profi le of the novel HIV integrase inhibitor elvitegravir. (JTK-303/GS-9137). J Virol 2008; 82(2):764-74.
21. Briz V, Garrido C, Poveda E et al. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 2009; 25(2):225-7.
22. Singh I, Gorzynski J, Drobysheva D, Bassit L, Schinazi R. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 2010; 5(4):e9948.
23. Fransen S, Gupta S, Paxinos E et al. Natural variation in susceptibility of patient-derived HIV-1 to an integrase strand transfer inhibitor. XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications; 2006.
24. Myers RE, Pillay D. Analysis of natural sequence variation and covariation in human immunodefi ciency virus type-1 integrase. J Virol 2008; 82(18):9228-9235.
25. Low A, Prada N, Topper M et al. Natural polymorphisms of human immunodefi ciency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother. 2009; 53(10):4275-4282.
26. Van Baelen K, Van Eygen V, Rondelez E, Stuyver LJ. Cladespecific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008; 22(14):1877-80.
27. Hazuda DJ, Anthony NJ, Gomez RP et al. From the Cover: A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA 2004; 101(31):11233-8.
28. Goethals O, Clayton R, Van Ginderen M et al. Resistance mutations in HIV type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82(21):10366-74.
29. Marinello J, Marchand C, Mott B, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008; 47(36):9345-54.
30. Fikkert V, Van Maele B, Vercammen J et al. Development of resistance against diketo derivatives of human immunodefi - ciency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77(21):11459-70.
31. Fikkert V, Hombrouck A, Van Remoortel B et al. Multiple mutations in human immunodefi ciency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004; 18(15):2019-28.
32. Jones G, Ledford R, Yu F, Miller MD, et al. Resistance profi le of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviruses and Opportunistic Infections Los Angeles. 2007.
33. McColl D, Fransen S, Gupta S et al. Resistance and cross-resistance to fi rst generation integrase inhibitors: insights from a Phase II study of elvitegravir (GS-9137). XVI International HIV Drug Resistance Workshop: Abstract 12. 2007.
34. Ceccherini-Silberstein F, Armenia D, D'Arrigo R et al. Virological response and resistance in multi-experienced patients treated with raltegravir. XVII International HIV Drug Resistance Workshop. Abstract 18. 2008.
35. Garvey EP, Johns BA, Gartland MJ et al. The naphthyridinone GSK364735 is a novel, potent human immunodefi ciency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother 2008; 52(3):901-908.
36. Hombrouck A, Voet A, Van Remoortel B et al. Mutations in human immunodefi ciency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother 2008; 52(6):2069-2078.
37. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52(4):1351-1358.
38. Cooper D, Steigbigel R, Gatell J et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359(4):355-65.
39. Charpentier C, Karmochkine M, Laureillard D et al. Drug resistance profi les for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008; 9(9):765-70.
40. Fransen S, Gupta S, Danovich R et al. Loss of raltegravir susceptibility of HIV-1 is conferred by multiple non-overlapping genetic pathways. J. Virol 2009; 83:11440-1446.
41. Hatano H, Lampiris H, Fransen S et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54(4):389-93.
42. Geretti A, Fearnhill E, Ceccherini-Silberstein F et al. Prevalence and patterns of raltegravir resistance in treated patients in Europe. 2010 XVIV International HIV Drug Resistance Workshop.
43. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advantage profi le of Human Immunodefi ciency virus type 1 integrase mutants explains In Vivo evolution of raltegravir resistance genotypes. J.Virol 2009; 83(19):10245-10249.
44. Soriano V, Garido C, Alverez E et al. Plasma raltegravir exposure infl uences the antiviral activity and selection of resistance mutations. 2010 International HIV and Hepatitis Virus Drug Resistance Workshop, Dubrovnik, Croatia.
45. Ferns R, Kirk S, Bennett J, et al. The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy. AIDS 2009; 23(16):2159-64.
46. Garrido C, Geretti A, Zahonero N et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010; 65(2):320-6.